Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 2
2006 1
2008 1
2009 2
2010 1
2011 1
2012 2
2013 1
2015 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Randomized, controlled trial of therapy interruption in chronic HIV-1 infection.
Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, Gallo C, Azzoni L, Foulkes A, Thiel B, Pistilli M, Mackiewicz A, Shull J, Montaner LJ. Papasavvas E, et al. PLoS Med. 2004 Dec;1(3):e64. doi: 10.1371/journal.pmed.0010064. Epub 2004 Dec 28. PLoS Med. 2004. PMID: 15630469 Free PMC article. Clinical Trial.
HIV-1-specific CD4+ T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption.
Papasavvas E, Kostman JR, Thiel B, Pistilli M, Mackiewicz A, Foulkes A, Gross R, Jordan KA, Nixon DF, Grant R, Poulin JF, McCune JM, Mounzer K, Montaner LJ. Papasavvas E, et al. J Clin Immunol. 2006 Jan;26(1):40-54. doi: 10.1007/s10875-006-7518-8. J Clin Immunol. 2006. PMID: 16418802 Clinical Trial.
Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patients.
Papasavvas E, Foulkes A, Yin X, Joseph J, Ross B, Azzoni L, Kostman JR, Mounzer K, Shull J, Montaner LJ. Papasavvas E, et al. Immunology. 2015 Jul;145(3):380-90. doi: 10.1111/imm.12452. Epub 2015 May 19. Immunology. 2015. PMID: 25684333 Free PMC article.
Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resumption of antiretroviral therapy.
Papasavvas E, Azzoni L, Pistilli M, Hancock A, Reynolds G, Gallo C, Ondercin J, Kostman JR, Mounzer K, Shull J, Montaner LJ. Papasavvas E, et al. AIDS. 2008 Jun 19;22(10):1153-61. doi: 10.1097/QAD.0b013e328303be2a. AIDS. 2008. PMID: 18525261 Free PMC article. Clinical Trial.
Retention of functional DC-NK cross-talk following up to 18 weeks therapy interruptions in chronically suppressed HIV type 1+ subjects.
Papasavvas E, Chehimi J, Azzoni L, Pistilli M, Thiel B, Mackiewicz A, Creer S, Mounzer K, Kostman JR, Montaner LJ. Papasavvas E, et al. AIDS Res Hum Retroviruses. 2010 Oct;26(10):1047-9. doi: 10.1089/aid.2010.0020. Epub 2010 Aug 18. AIDS Res Hum Retroviruses. 2010. PMID: 20718621 Free PMC article. No abstract available.
13 results